BeyondSpring Inc.

NasdaqCM:BYSI Stock Report

Market Cap: US$67.8m

BeyondSpring Past Earnings Performance

Past criteria checks 0/6

BeyondSpring has been growing earnings at an average annual rate of 46.6%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been declining at an average rate of 42.8% per year.

Key information

46.63%

Earnings growth rate

48.70%

EPS growth rate

Biotechs Industry Growth17.04%
Revenue growth rate-42.82%
Return on equityn/a
Net Marginn/a
Last Earnings Update31 Mar 2026

Recent past performance updates

Recent updates

Analysis Article • Apr 28

Can BeyondSpring (NASDAQ:BYSI) Afford To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • Sep 24

We Think BeyondSpring (NASDAQ:BYSI) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 10

Here's Why BeyondSpring (NASDAQ:BYSI) Must Use Its Cash Wisely

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jun 21

Here's Why We're Watching BeyondSpring's (NASDAQ:BYSI) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Feb 03

BeyondSpring, Beyond Salvage

BYSI was handed a CRL last year. NSCLC data has also been called into question. The future looks bleak.
Seeking Alpha • Nov 16

Circling Back On BeyondSpring

Today, we look back in on a small oncology company called BeyondSpring for the first time since early this year. The stock quadrupled in August on good trial results but has fallen back 40% since then on some doubts around the data. Temporary setback or beginning of a larger move down? A full investment analysis is provided in the paragraphs below.
Seeking Alpha • Sep 18

Upcoming News For BeyondSpring's Plinabulin Tees Up Big Potential Returns

BeyondSpring Pharmaceuticals has the potential to address the billion-dollar anti-cancer markets on top of a large unmet medical need to reduce chemo-induced neutropenia (CIN) with revenues beginning in early 2022. On Monday morning 9/20/21, BeyondSpring will present at ESMO late breaking Phase 3 trial data on Plinabulin to potentially extend survival for Non-Small Cell Lung Cancer (NSCLC) patients. Importantly, FDA approval for CIN by the 11/30/21 PDUFA date will trigger early 2022 commercial launch in the U.S. and give investors greater confidence of FDA approval for NSCLC despite somewhat controversial trial designs. Regulatory approvals for Plinabulin for CIN and NSCLC in both the US and China contribute to our estimated revenues of $127, $330 and $638 million in 2022, 2023 and 2024 and EPS of $4/share and a target price of $120/share by 2024. Further upside potential from Triple I/O Phase 2 data in Small Cell Lung Cancer (SCLC) in 2022, 7-cancer basket trial Phase 1 data in 2022 and SEED Therapeutics protein degradation.
Seeking Alpha • Sep 07

BeyondSpring: Poor Trial Conduct And Lack Of Transparency Create Substantial Downside Risk

Recently announced Phase 3 lung cancer data is likely weaker than claimed given the lack of standard disclosure and a history of poor trial conduct. We identify inaccurate data reporting and contradictory management statements regarding critical trial issues. Both strongly suggest BYSI is incapable of producing an adequate NDA. BeyondSpring’s chemotherapy-induced neutropenia US NDA is based on a Phase 3 trial that only enrolled in China and Ukraine. We find it hard to believe such data will satisfy FDA. Two leading oncologists express skepticism regarding Plinabulin’s data and approvability in neutropenia and lung cancer. Base case: Lung cancer data is less than claimed and FDA denial in neutropenia. Shares are worth $5/share (cash plus protein degrader platform value).
Seeking Alpha • Aug 01

BeyondSpring's Plinabulin: Upcoming PDUFA And Positioning In The CIN Space

BYSI has a November PDUFA for plinabulin in chemo-induced neutropenia. There are certain ways in which plinabulin and Spectrum's rolontis complement each other. Below is an overview of plinabulin and a comparison.
Analysis Article • Dec 22

How Much Of BeyondSpring Inc. (NASDAQ:BYSI) Do Insiders Own?

A look at the shareholders of BeyondSpring Inc. ( NASDAQ:BYSI ) can tell us which group is most powerful. Institutions...

Revenue & Expenses Breakdown

How BeyondSpring makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

NasdaqCM:BYSI Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 260-845
31 Dec 250-854
30 Sep 250-853
30 Jun 250-863
31 Mar 250-973
31 Dec 240-863
30 Jun 24-1-560
31 Mar 240-973
31 Dec 230-1387
30 Sep 232-241018
30 Jun 232-281121
31 Mar 231-301223
31 Dec 221-331326
30 Sep 221-351526
30 Jun 221-462328
31 Mar 221-562833
31 Dec 211-643137
30 Sep 211-723640
30 Jun 211-683340
31 Mar 211-622639
31 Dec 200-612342
30 Sep 200-571546
30 Jun 200-521145
31 Mar 200-471039
31 Dec 190-38931
30 Sep 190-38931
30 Jun 190-44838
31 Mar 190-49744
31 Dec 180-55652
30 Sep 180-56554
30 Jun 180-57755
31 Mar 180-58956
31 Dec 170-92989
30 Sep 170-80877
30 Jun 170-67565
31 Mar 170-58356
31 Dec 160-12210
30 Sep 160-1029
30 Jun 160-928
31 Mar 160-816

Quality Earnings: BYSI is currently unprofitable.

Growing Profit Margin: BYSI is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BYSI is unprofitable, but has reduced losses over the past 5 years at a rate of 46.6% per year.

Accelerating Growth: Unable to compare BYSI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BYSI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).

Return on Equity

High ROE: BYSI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/12 21:14
End of Day Share Price 2026/06/12 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BeyondSpring Inc. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Joel BeattyBaird
Jason Matthew GerberryBofA Global Research
Joshua SchimmerEvercore ISI